Recent Updates
Recently added Catalysts

BB102

Phase 2

Hepatocellular Carcinoma (HCC) | Small molecule | Oncology |Co-Diagnostics, Inc.|Last Updated: Nov 20, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment60
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT07239986A Phase 2 Study of BB102 in Patients With Hepatocellular CarcinomaPHASE2 NOT YET_RECRUITING 60 — — Dec 1, 2025Jun 1, 2028Nov 20, 20252 China
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Objective response rate (ORR)
From enrollment to the end of treatment assessed up to 12 months

Tumor response measured by radiologic imaging techniques at baseline and throughout the study.

Secondary Endpoints
Disease control rate (DCR)
From enrollment to the end of treatment assessed up to 12 months
Duration of response (DOR)
From enrollment to the end of treatment assessed up to 12 months
Progression-free survival (PFS)
From enrollment to the end of treatment assessed up to 12 months
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
BB102 treatmentEXPERIMENTAL -
Interventions
NameTypeDescription
BB102DRUGOral BB102 Tablets in two dosage
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites2

Inclusion Criteria: * (1) Age ≥ 18 years old, with no gender restrictions. * (2) Disease progressed after receiving at least one anti-angiogenic and/or immune checkpoint inhibitor (including PD-1, PD-L1, CTLA-4) therapy, or the treatment is not tolerable. * (3) Histologically confirmed primary HCC ...

Countries:China
Unlock Eligibility Criteria